Related Experiment Video

Updated: Dec 3, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.2K

Current perspectives on the treatment of BRAF mutated colorectal carcinoma

Stanislav Batko

    Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti
    |October 28, 2020
    PubMed
    Abstract

    Insights

    The BEACON trial introduces a new standard for BRAF-mutated colorectal cancer treatment. Encorafenib plus cetuximab significantly improves overall survival and response rates, offering a well-tolerated option for patients with poor prognoses.

    Area of Science:

    • Oncology
    • Molecular Diagnostics
    • Cancer Subtypes

    Background:

    • Metastatic colorectal cancer (CRC) is a leading cause of cancer death globally.
    • BRAF-mutated CRC represents a challenging subgroup with poor prognosis and limited treatment efficacy.
    • Current first-line treatments for metastatic CRC involve chemotherapy combined with antiangiogenic antibodies, with few options for subsequent lines of therapy.

    Purpose of the Study:

    • To review current treatment strategies for BRAF-mutated colorectal cancer.
    • To highlight recent advancements in managing this specific cancer subtype.

    Main Methods:

    • Review of current literature and clinical trial data.
    • Analysis of treatment outcomes for BRAF-mutated colorectal cancer.

    Main Results:

    • The BEACON trial demonstrated superior overall survival and response rates with encorafenib plus cetuximab compared to standard therapy in BRAF-mutated CRC.
    • This combination therapy exhibited a manageable safety profile with well-tolerated toxicities.
    • Encorafenib plus cetuximab represents a new standard of care for previously untreated metastatic BRAF-mutated CRC.

    Conclusions:

    • Encorafenib plus cetuximab offers a significant therapeutic advancement for patients with BRAF-mutated metastatic colorectal cancer.
    • This targeted therapy combination addresses the unmet need for effective treatment options in this poor-prognosis subgroup.
    Keywords:
    BEACONBRAF V600Ebinimetinibcetuximabencorafenibmetastatic colorectal cancer

    More Related Videos

    Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer06:19

    Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

    Published on: July 18, 2017

    10.5K
    Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

    Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

    Published on: September 8, 2021

    3.2K

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.6K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    8.2K
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    5.7K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    4.4K
    Cancer Therapies02:49

    Cancer Therapies

    Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
    However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
    9.5K